Abstract
A novel series of 4-(1,2,3-triazol-1-yl) salicylic acid derivatives was synthesized from 4-azidosalicylic acid and diverse alkynes using copper catalyzed azide-alkyne cycloaddition as key process and fully characterized by using different analytical techniques. The in vitro antiproliferative activity of these new compounds was explored against a series of tumoral cell lines which included U251 (human glioblastoma), PC-3 (human prostate cancer cell line), K562 (human leukemia), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human breast adenocarcinoma) and SKLU (human lung adenocarcinoma), showing selective activity in some compounds. Moreover, molecular docking studies suggest a strong interaction between ARG-154 in STAT3 and the triazole fragment which can explain the inhibitory activity observed in these compounds.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
